The progress in molecular biomarkers of gliomas
Malignant glioma, a common form of central nervous system tumor, has a poor prognosis. The overall survival of these patients is as low as 12–14 months only. In general, the progress in personal precision medication has been gradually directed toward the molecular profiling of the tumors. Malignant...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2016-01-01
|
Series: | Cancer Translational Medicine |
Subjects: | |
Online Access: | http://www.cancertm.com/article.asp?issn=2395-3977;year=2016;volume=2;issue=4;spage=125;epage=129;aulast=Qi |